Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
157.44
+3.53 (2.29%)
At close: Apr 17, 2025, 4:00 PM
157.47
+0.03 (0.02%)
After-hours: Apr 17, 2025, 7:15 PM EDT
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $21.89B in the quarter ending March 30, 2025, with 2.39% growth. This brings the company's revenue in the last twelve months to $89.33B, up 4.30% year-over-year. In the year 2024, Johnson & Johnson had annual revenue of $88.82B with 4.30% growth.
Revenue (ttm)
$89.33B
Revenue Growth
+4.30%
P/S Ratio
4.24
Revenue / Employee
$646,857
Employees
138,100
Market Cap
379.48B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
Dec 29, 2019 | Pro | Pro | Pro |
Dec 30, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Jan 1, 2017 | Pro | Pro | Pro |
Jan 3, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
Abbott Laboratories | 42.34B |
JNJ News
- 18 hours ago - Why Most Dividend Retirement Strategies Fail: How To Retire With Dividends - Seeking Alpha
- 1 day ago - Johnson & Johnson to Participate in the 2025 RBC Capital Markets Global Healthcare Conference - Business Wire
- 1 day ago - Healthy Returns: What drugmakers are saying about Trump's looming pharmaceutical tariffs - CNBC
- 2 days ago - Two New Dividend Picks To Help You Navigate Tariffs And Uncertainty -- One Yields 7%+ - Seeking Alpha
- 2 days ago - Johnson & Johnson (JNJ) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Johnson & Johnson: First Look At Q1 Earnings - Solid Quarter Will Calm Nerves - Seeking Alpha
- 2 days ago - Johnson & Johnson raised its sales outlook, even with tariff costs included - Market Watch
- 2 days ago - Johnson & Johnson Tops Q1 Estimates, Lifts Full-Year Sales Outlook - Investopedia